Esperion Therapeutics (ESPR) Misses Q4 EPS by 13c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
February 23, 2021 4:01 PM ESTFourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S.CLEAR Outcomes Study Design Highlighted in The American Heart Journal and Progresses Uninterrupted Despite PandemicConference Call and Webcast Today, February 23rd at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:... More
